Home » Healthcare » Pharmaceuticals » Neutropenia Treatment Market

Neutropenia Treatment Market By Drug Type (G-CSF, GM-CSF, Antibiotics, Antifungal, Antiviral), By Pipeline Analysis (Plinabulin – Phase 2/3, EC-18 – Phase 2, SPI-2012 – Phase 3, rHSA-GCSF 2.4mg – Phase 2, Probio-Fix Inum – Phase 2, Pegteograstim – Phase 2, F-627 – Phase 3, Astragalus polysaccharides 500 mg – Phase 2, Leucostim – Phase 3, myelo001 – Phase 3, Romyelocel-L – Phase 3) – Growth, Future Prospects and Competitive Analysis, 2019-2027

Summary
Table Of Content

Market Insights

Neutropenia treatment accounted for a market value of US$ 11,279.2 million in 2018 and is projected to grow at a CAGR of 5.0% during the forecast period from 2019 to 2027. In neutropenia, the count of neutrophils falls, giving rise to compromised immunity and further increasing the risk of infection. Neutropenia is observed in almost half of all cancer patients being treated with chemotherapy, but of those, most are suffering from leukemia. According to medical experts, neutropenia can be a chronic condition because, without adequate neutrophils, patients become vulnerable to life-threatening infections.

Market Synopsis

A strong drug pipeline will assist the significant growth of the neutropenia treatment market throughout the forecast period.

The drug pipeline for neutropenia treatment is equipped with several promising drugs in phase III of clinical trials, such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon Shanghai Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals, Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.).

Neutropenia is caused by several factors, the major one being the post-chemotherapy decrease in neutrophil count. An increasing prevalence of leukemia is expected to raise the number of neutropenia cases, as chemotherapy is the first-line treatment for leukemia. However, a precautionary treatment regimen is ready to avoid the effects of neutropenia-based infections with antibacterial, antiviral, and antifungal drugs.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

North America dominated the overall global market specifically due to a promising drug pipeline and a developed diagnostic landscape.

In 2018, North America dominated the market and was expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, the increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectations from drugs in the pipeline.

According to several studies, the prevalence of neutropenia is around 4.4% and is expected to increase in specific regions with the rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis and treatment, coupled with the development of diagnostic technologies in the rare disease sector.

Historical and Forecast Period

The neutropenia treatment market was analyzed considering current market trends for the base year of 2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises detailed qualitative and quantitative data related to the neutropenia treatment market, along with key factors related to the market, such as opportunities, drivers, and restraints. An elaborative analysis covering market drivers, challenges, and opportunities is provided explicitly for country-level and regional segmentation.

This report covered brief information associated with the global neutropenia treatment market segmented by such factors as drug class, type, and geography. The pipeline analysis of the neutropenia treatment market comprises drugs under trial in preclinical studies phases I, II, and III. Competitive analysis of the major companies is included in the neutropenia treatment market, along with detailed data related to the competitive landscape of the market and recent strategies and products entering the market.

The key companies included in the neutropenia treatment industry were analyzed based on financial data, product portfolios, current press releases, and major market strategies. This report also includes attractive investment propositions studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc.; Spectrum Pharmaceuticals, Inc.; Generon (Shanghai) Corporation Ltd.; Dong-A ST Co., Ltd.; BeyondSpring Pharmaceuticals, Inc.; Myelo Therapeutics, Inc.; Cellerant Therapeutics, Inc.; and Sandoz (a subsidiary of Novartis AG), among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Which is the most frequent drug class to manage and treat neutropenia, and why?
What are the novel marketing strategies followed by the major companies and the competitive landscape of the neutropenia treatment market?
Which are the recent and upcoming drugs in the neutropenia treatment market?
Which is the largest and fastest-growing neutropenia treatment segment globally?
What are the drivers, restraints, and opportunities in the neutropenia treatment market?
Which are the major geographical markets (regions and countries) of the neutropenia treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global NT Market Portraiture
2.2. Global NT Market, by Type of Drug Class, 2018 (US$ Mn)
2.3. Global NT Market, by Geography, 2018 Vs 2027 (Value %)

Chapter 3. Global Neutropenia Treatment (NT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Neutropenia Treatment (NT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Granulocyte-colony stimulating factor (G-CSF)
4.3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
4.4. Antibiotics
4.5. Antifungal
4.6. Antiviral

Chapter 5. Global Neutropenia Treatment (NT) Market, Pipeline Analysis
5.1. Overview
5.2. Plinabulin – Phase 2/3 (BeyondSpring Pharmaceuticals Inc.)
5.3. EC-18 – Phase 2 (Enzychem Lifesciences Corporation)
5.4. SPI-2012 – Phase 3 (Spectrum Pharmaceuticals, Inc.)
5.5. rHSA-GCSF 2.4mg – Phase 2 (Tianjin SinoBiotech Ltd.)
5.6. Probio-Fix Inum – Phase 2 (S&D Pharma SK s.r.o.)
5.7. Pegteograstim – Phase 2 (Samsung Medical Center)
5.8. F-627 – Phase 3 (Generon (Shanghai) Corporation Ltd.)
5.9. Astragalus polysaccharides 500 mg – Phase 2 (PhytoHealth Corporation)
5.10. Leucostim – Phase 3 (Dong-A ST Co., Ltd.)
5.11. myelo001 – Phase 3 (Myelo Therapeutics, Inc.)
5.12. Romyelocel-L – Phase 3 (Cellerant Therapeutics, Inc.)

Chapter 6. Global Neutropenia Treatment (NT) Market, by Geography, 2017 – 2027 (US$ Mn)
6.1. Overview
6.2. North America NT Market Analysis, 2017 – 2027
6.2.1. North America NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.2.2. North America NT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe NT Market Analysis, 2017 – 2027
6.3.1. Europe NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.3.2. Europe NT Market, by Country, 2017 – 2027 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific NT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.4.2. Asia Pacific NT Market, by Country, 2017 – 2027 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America NT Market Analysis, 2017 – 2027
6.5.1. Latin America NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.5.2. Latin America NT Market, by Country, 2017 – 2027 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) NT Market Analysis, 2017 – 2027
6.6.1. Middle East & Africa NT Market, by Type of Drug Class, 2017–2027 (US$ Mn)
6.6.2. MEA NT Market, by Region, 2017 – 2027 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Pfizer, Inc.
7.3. Myelo Therapeutics, Inc.
7.4. Cellerant Therapeutics, Inc.
7.5. Sandoz (Subsidary of Novartis AG)
7.6. BeyondSpring Pharmaceuticals Inc.
7.7. Enzychem Lifesciences Corporation
7.8. Spectrum Pharmaceuticals, Inc.
7.9. Tianjin SinoBiotech Ltd.
7.10. S&D Pharma SK s.r.o.
7.11. Samsung Medical Center
7.12. Generon (Shanghai) Corporation Ltd.
7.13. PhytoHealth Corporation
7.14. Dong-A ST Co., Ltd.

List Of Figures

FIG. 1 Neutropenia Treatment (NT): Market Segmentation
FIG. 2 Global NT Market Share, by Type of Drug Class, 2018 (US$ Mn)
FIG. 3 Global NT Market, by Geography, 2018 Vs 2027 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2018
FIG. 5 Market Competition Landscape, by Key Players, 2018
FIG. 6 Global Granulocyte-colony stimulating factor (G-CSF) Market for NT, 2017 – 2027 (US$ Mn)
FIG. 7 Global Granulocyte-macrophage colony-stimulating factor (GM-CSF) Market for NT, 2017 – 2027 (US$ Mn)
FIG. 8 Global Antibiotics Market for NT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Antifungal Market for NT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Antiviral Market for NT, 2017 – 2027 (US$ Mn)
FIG. 11 Global Plinabulin Market for NT, Till 2027 (US$ Mn)
FIG. 12 Global SPI-2012 Market for NT, Till 2027 (US$ Mn)
FIG. 13 Global Leucostim Market for NT, Till 2027 (US$ Mn)
FIG. 14 Global myelo001 Market for NT, Till 2027 (US$ Mn)
FIG. 15 Global Romyelocel-L Market for NT, Till 2027 (US$ Mn)
FIG. 16 U.S. NT Market, 2017 – 2027 (US$ Mn)
FIG. 17 Canada NT Market, 2017 – 2027 (US$ Mn)
FIG. 18 U.K. NT Market, 2017 – 2027 (US$ Mn)
FIG. 19 Germany NT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Rest Of Europe NT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Japan NT Market, 2017 – 2027 (US$ Mn)
FIG. 22 China NT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Rest Of Asia Pacific NT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Brazil NT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Mexico NT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest Of Latin America NT Market, 2017 – 2027 (US$ Mn)
FIG. 27 GCC NT Market, 2017 – 2027 (US$ Mn)
FIG. 28 Rest Of Middle East And Africa NT Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Neutropenia Treatment (NT) Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 2 North America NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 3 North America NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 4 Europe NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 5 Europe NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 6 Asia Pacific NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 7 Asia Pacific NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 8 Latin America NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 9 Latin America NT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 10 Middle East & Africa NT Market, by Type of Drug Class, 2017 – 2027 (US$ Mn)
TABLE 11 Middle East And Africa NT Market, by Region, 2017 – 2027 (US$ Mn)
TABLE 12 Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Myelo Therapeutics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cellerant Therapeutics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Sandoz (Subsidary of Novartis AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 BeyondSpring Pharmaceuticals Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Enzychem Lifesciences Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Spectrum Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Tianjin SinoBiotech Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 S&D Pharma SK s.r.o. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Samsung Medical Center: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Generon (Shanghai) Corporation Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 PhytoHealth Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Dong-A ST Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Neutropenia Treatment Market?

The market for Neutropenia Treatment Market is expected to reach USD$ 11,279.2 Mn in 2027.

What is the Neutropenia Treatment Market CAGR?

The Neutropenia Treatment Market is expected to see significant CAGR growth over the coming years, at 5.0%

What is the Forecast period considered for Neutropenia Treatment Market?

The report is forecasted from 2019 -2027.

What is the base year considered for Neutropenia Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

Amgen, Inc.; Spectrum Pharmaceuticals, Inc.; Generon (Shanghai) Corporation Ltd. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –